New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
11:00 EDTAZNAstraZeneca unit says MEDI4736 studies showed clinical activity
MedImmune, the biologics research and development arm of AstraZeneca, presented results from its novel investigational immunotherapy portfolio, focusing on MEDI4736, at the American Society of Clinical Oncology meeting. "Overall, studies demonstrated durable and tolerability for MEDI4736 across a range of tumor types," the company said. In a Phase I dose-escalation study of MEDI4736 in 27 patients with advanced solid tumors, reduction of tumor burden was seen at multiple dose levels in as early as six weeks. Clinical activity was maintained for at least one year, with 19% of patients achieving a partial response and 39% of patients achieving disease control. "There was a very low frequency of drug-related serious adverse events, and no dose-limiting toxicities were observed," Medimmune added.
News For AZN From The Last 14 Days
Check below for free stories on AZN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 16, 2014
10:36 EDTAZNTreasury calls on Congress to halt inversion deals
Subscribe for More Information
08:01 EDTAZNAlexion names former AstraZeneca CEO David Brennan to board
Subscribe for More Information
07:59 EDTAZNTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
July 8, 2014
07:17 EDTAZNLeerink raises immuno-oncology market forecast to $36B
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use